Ruxolitinib (INCB18424) Clinical Trials

Size	Price	Qty
5mg	USD 160
25mg	USD 320

Clinical Trials

Numerous clinical trials evaluate ruxolitinib across Early Phase 1 through Phase 4 stages, investigating conditions such as myelofibrosis, polycythemia vera, acute myeloid leukemia, graft-versus-host disease, and breast cancer. Sponsored by pharmaceutical organizations like Incyte Corporation and Gilead Sciences alongside academic institutions including M.D. Anderson Cancer Center, these studies range in status from active recruitment to completed investigations. Overall, this broad research effort highlights the established therapeutic role and expanding clinical evaluation of ruxolitinib.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06768476	ACTIVE_NOT_RECRUITING	Relapsed AML; Refractory AML	University of Pennsylvania	2025-02-28	PHASE1
NCT07297914	NOT_YET_RECRUITING	Acute Lymphoblastic Leukemia (ALL); Stem Cell Transplant; Graft -Versus-host-disease	Bambino Gesù Hospital and Research Institute	2026-01-15	PHASE2; PHASE3
NCT07722611	NOT_YET_RECRUITING	Polycythemia Vera	Merck Sharp & Dohme LLC	2026-09-21	PHASE2; PHASE3
NCT02386800	ACTIVE_NOT_RECRUITING	Primary Myelofibrosis; Polycythemia Vera; Graft Versus Host Disease; Acute Myeloid Leukemia; Thalassemia	Novartis Pharmaceuticals	2015-03-05	PHASE4
NCT04744116	RECRUITING	Hematopoietic and Lymphoid Cell Neoplasm; Steroid Refractory Graft Versus Host Disease	M.D. Anderson Cancer Center	2021-02-17	EARLY_PHASE1
NCT05745714	RECRUITING	Acute Lymphoblastic Leukemia, in Relapse; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent; Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory; Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory	Princess Maxima Center for Pediatric Oncology	2025-10-01	PHASE1; PHASE2
NCT07128381	RECRUITING	Myelofibrosis (MF); Chronic Myelomonocytic Leukemia (CMML)	M.D. Anderson Cancer Center	2026-01-02	PHASE1; PHASE2
NCT06615050	RECRUITING	Graft-versus-host Disease (GVHD)	Incyte Corporation	2025-04-02	PHASE3
NCT06991101	RECRUITING	Glioblastoma; Brain Cancer; Glioblastoma Multiforme; Glioblastoma Multiforme of Brain; Glioblastoma Multiforme, Adult; MGMT-Unmethylated Glioblastoma; MGMT-Methylated Glioblastoma	Baptist Health South Florida	2025-12-03	PHASE2
NCT06128070	RECRUITING	Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Myelodysplastic Syndrome	City of Hope Medical Center	2024-07-16	PHASE2
NCT07228624	RECRUITING	Myelodysplastic/Myeloproliferative Neoplasm; Primary Myelofibrosis; Secondary Myelofibrosis	Fred Hutchinson Cancer Center	2026-02-04	PHASE2
NCT07352566	NOT_YET_RECRUITING	Psoriasis; Atopic Dermatitis	University of California, San Francisco	2026-08-01	PHASE4
NCT05088226	RECRUITING	Peripheral Blood Stem Cell Transplantation	Chinese PLA General Hospital	2021-12-01	PHASE2
NCT07794514	RECRUITING	Hematopoietic Stem Cell Transplantation (HSCT); cGVHD; Hepatic cGVHD; Belumosudil; Ruxolitinib	First Affiliated Hospital of Zhejiang University	2026-10-01
NCT07623161	RECRUITING	Myelofibrosis; Anemia	Takeda	2026-09-02	PHASE3
NCT07566897	NOT_YET_RECRUITING	Renal Carcinoma Metastatic; Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Metastatic Colorectal Carcinoma (mCRC)	Philogen S.p.A.	2026-05-01	PHASE1
NCT07801248	NOT_YET_RECRUITING	Acute Skin Graft Versus Host Disease (GVHD)	Children's Hospital Medical Center, Cincinnati	2026-10-01	PHASE1
NCT07783412	NOT_YET_RECRUITING	Pyoderma Gangrenosum	Oregon Health and Science University	2026-09-01	PHASE2
NCT07498205	NOT_YET_RECRUITING	Myelofibrosis; Myelofibrosis (MF)	SWOG Cancer Research Network	2026-08-08	PHASE4
NCT07521046	NOT_YET_RECRUITING	Myelofibrosis	University of Utah	2026-08	PHASE1
NCT07643025	NOT_YET_RECRUITING	cGVHD	Dennis Kim	2026-07	PHASE2
NCT07464951	RECRUITING	Acute Myeloid Leukemia (AML)	Stephan Grupp MD PhD	2026-05-14	PHASE1
NCT06824103	RECRUITING	Graft vs. Host Disease; Chronic Graft vs. Host Disease; Corticosteroid-refractory Chronic Graft vs. Host Disease	Novartis Pharmaceuticals	2025-09-09	PHASE4
NCT06327100	RECRUITING	Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-Essential Thrombocytosis Myelofibrosis	M.D. Anderson Cancer Center	2024-08-01	PHASE1; PHASE2
NCT06291987	RECRUITING	Myeloproliferative Neoplasms	University of Chicago	2024-09-19	PHASE1
NCT03801434	ACTIVE_NOT_RECRUITING	BCR-JAK2 Fusion Protein Expression; Blasts 20 Percent or Less of Peripheral Blood White Cells; Blasts More Than 5 Percent of Bone Marrow Nucleated Cells; Blasts More Than 5 Percent of Peripheral Blood White Cells; Blasts Under 20 Percent of Bone Marrow Nucleated Cells; Chronic Eosinophilic Leukemia, Not Otherwise Specified; Eosinophilia; Hepatomegaly; Hypereosinophilic Syndrome; JAK2 Gene Mutation; Splenomegaly; TEL-JAK2 Fusion Protein Expression	Stanford University	2019-11-15	PHASE2
NCT07311746	RECRUITING	T-cell Prolymphocytic Leukemia; Refractory T-Cell Prolymphocytic Leukemia	M.D. Anderson Cancer Center	2026-04-28	PHASE1; PHASE2
NCT06233110	RECRUITING	Chronic Graft Versus Host Disease	Stefanie Sarantopoulos, MD, PhD.	2025-10-29	PHASE1
NCT07359859	RECRUITING	Hematologic Malignancies	Memorial Sloan Kettering Cancer Center	2026-01-20	PHASE2
NCT06508463	RECRUITING	Peripheral T Cell Lymphoma; Relapsed Peripheral T-Cell Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified; Anaplastic Large Cell Lymphoma; Mycosis Fungoides; Relapsed Anaplastic Large Cell Lymphoma; Relapsed Mycosis Fungoides	Mayo Clinic	2024-01-05	PHASE1
NCT06160791	RECRUITING	Hemophagocytic Lymphohistiocytoses	Jerry Lee, MD, MSc, MPhil	2024-10-01	PHASE2
NCT07595939	NOT_YET_RECRUITING	Vitiligo	The Children's Hospital of Zhejiang University School of Medicine	2026-06-01	PHASE3
NCT03017820	RECRUITING	B-Cell Non-Hodgkin Lymphoma; Histiocytic and Dendritic Cell Neoplasm; Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Recurrent Anaplastic Large Cell Lymphoma; Recurrent Angioimmunoblastic T-Cell Lymphoma; Recurrent Mycosis Fungoides; Recurrent Plasma Cell Myeloma; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Acute Myeloid Leukemia; Refractory Anaplastic Large Cell Lymphoma; Refractory Angioimmunoblastic T-Cell Lymphoma; Refractory Mycosis Fungoides; Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified; Refractory Plasma Cell Myeloma; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma	Mayo Clinic	2017-04-04	PHASE1
NCT07734077	NOT_YET_RECRUITING	Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis	John Mascarenhas	2026-12-01	PHASE1; PHASE2
NCT06660355	RECRUITING	Chronic Graft-versus-host Disease (cGVHD)	H. Lee Moffitt Cancer Center and Research Institute	2024-12-23	PHASE2
NCT07252050	RECRUITING	Sickle Cell Disease; Hematopoetic Stem Cell Transplant; Haploidentical Hematopoietic Stem Cell Transplant; Haploidentical Stem Cell Transplantation; Graft Failure	Arkansas Children's Hospital Research Institute	2026-06-08	PHASE1; PHASE2
NCT04116502	RECRUITING	Polycythemia Vera	University of Birmingham	2019-10-25	PHASE3
NCT06034002	RECRUITING	Myeloproliferative Neoplasms	Incyte Corporation	2023-12-04	PHASE1
NCT02131584	ACTIVE_NOT_RECRUITING	Chronic Lymphocytic Leukemia	M.D. Anderson Cancer Center	2014-09-02	PHASE2
NCT04817007	ACTIVE_NOT_RECRUITING	Myelofibrosis	Bristol-Myers Squibb	2021-03-22	PHASE1; PHASE2
NCT07085039	RECRUITING	Castleman's Disease (CD); Idiopathic Multicentric Castleman's Disease	University of Pennsylvania	2025-12-18	PHASE2
NCT07424222	RECRUITING	Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2026-07-15	PHASE1
NCT07025538	RECRUITING	Hematopoietic and Lymphatic System Neoplasm	City of Hope Medical Center	2026-04-29	PHASE1
NCT06536166	RECRUITING	Inclusion Body Myositis, Sporadic	Assistance Publique - Hôpitaux de Paris	2025-05-27	PHASE2
NCT06477549	RECRUITING	Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Biphenotypic Acute Leukemia; Lymphoblastic Lymphoma; Myeloproliferative Neoplasm; Myelodysplastic Syndromes	St. Petersburg State Pavlov Medical University	2024-06-21	PHASE2
NCT06859424	RECRUITING	AML (Acute Myelogenous Leukemia); Acute Lymphoid Leukemia (ALL); Acute Leukemia (Category); MDS (Myelodysplastic Syndrome); CML (Chronic Myelogenous Leukemia); CLL (Chronic Lymphocytic Leukemia); Prolymphocyctic Leukemia; Chronic Myelomonocytic Leukemia (CMML); Myeloproliferative Neoplasm (MPN); Lymphoma; Myelofibrosis	Center for International Blood and Marrow Transplant Research	2025-07-25	PHASE2
NCT06616155	RECRUITING	Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8	University of Michigan Rogel Cancer Center	2026-06	PHASE1; PHASE2
NCT07357727	RECRUITING	Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (PPV-MF); Post-essential Thrombocythemia Myelofibrosis (PET-MF)	Novartis Pharmaceuticals	2026-06-16	PHASE3
NCT07131059	RECRUITING	AML, Adult	Institute of Hematology & Blood Diseases Hospital, China	2024-05-11
NCT05088356	ACTIVE_NOT_RECRUITING	Allogeneic Hematopoietic Cell Transplantation (HCT); Advanced Hematologic Malignancies; Acute Leukemia; Chronic Myelogenous Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders	Stanford University	2021-09-07	PHASE1
NCT05870475	RECRUITING	Polycythemia Vera	Institute of Hematology & Blood Diseases Hospital, China	2023-06-30	PHASE2
NCT06887803	RECRUITING	Myelofibrosis (MF)	iOnctura	2025-11-17	PHASE1; PHASE2
NCT05936359	ACTIVE_NOT_RECRUITING	Myeloproliferative Neoplasms	Incyte Corporation	2023-09-25	PHASE1
NCT07568535	NOT_YET_RECRUITING	GVHD - Graft-Versus-Host Disease	Mesoblast, Ltd.	2026-08-31	PHASE3
NCT05037760	RECRUITING	Myelofibrosis	Takeda	2021-12-16	PHASE2
NCT06973668	RECRUITING	AML	M.D. Anderson Cancer Center	2025-07-22	PHASE2
NCT07101588	RECRUITING	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)	Chinese PLA General Hospital	2025-01-01	PHASE4
NCT06773195	RECRUITING	Myelofibrosis	Memorial Sloan Kettering Cancer Center	2025-01-07	PHASE1; PHASE2
NCT07283822	RECRUITING	Non-Hodgkin Lymphoma; Hodgkin Disease Lymphoma; Non-Hodgkin Lymphoma Refractory/ Relapsed; Hodgkin Disease Recurrent; Gray Zone Lymphoma; Peripheral T-cell Lymphoma; Cutaneous T-Cell Lymphomas; Primary Mediastinal B Cell Lymphoma	Seda S. Tolu	2025-12-03	PHASE2
NCT03874052	RECRUITING	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia; Recurrent Secondary Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia; Refractory Secondary Acute Myeloid Leukemia	Jennifer Saultz	2019-08-16	PHASE1
NCT07548983	RECRUITING	Acute Myeloid Leukemia	OHSU Knight Cancer Institute	2026-04-21	PHASE1
NCT07588945	NOT_YET_RECRUITING	Transplant-Related Disorder	Institute of Hematology & Blood Diseases Hospital, China	2026-06-01	PHASE3
NCT06364319	NOT_YET_RECRUITING	cGVHD	Peking University People's Hospital	2026-07-15	PHASE4
NCT07576010	ACTIVE_NOT_RECRUITING	Acute Graft-versus-host Disease	Daihong Liu	2025-01-17	PHASE1
NCT07317700	RECRUITING	MF	Chengdu Zenitar Biomedical Technology Co., Ltd	2026-02-13	PHASE3
NCT07509749	RECRUITING	GVHD, Acute; Stem Cell Transplant Complications	Daihong Liu	2025-06-30	PHASE2
NCT05398809	RECRUITING	Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced); Alopecia Areata	National Institute of Allergy and Infectious Diseases (NIAID)	2023-01-18	PHASE2
NCT07219576	RECRUITING	Non Small Cell Lung Carcinoma; Renal Cell Carcinoma	University of California, San Diego	2026-01-08	PHASE1; PHASE2
NCT02577926	ACTIVE_NOT_RECRUITING	Polycythemia Vera (PV); Essential Thrombocythemia (ET)	RWTH Aachen University	2015-10	PHASE2
NCT05098210	RECRUITING	Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Locally Advanced Cutaneous Melanoma; Locally Advanced Mucosal Melanoma; Metastatic Acral Melanoma; Metastatic Conjunctival Melanoma; Metastatic Cutaneous Melanoma; Metastatic HER2-Negative Breast Carcinoma; Metastatic Hormone Receptor-Positive Breast Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Mucosal Melanoma; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8; Recurrent Cutaneous Melanoma; Recurrent HER2-Negative Breast Carcinoma; Recurrent Hormone Receptor-Positive Breast Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Recurrent Mucosal Melanoma; Stage III Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Unresectable Acral Melanoma; Unresectable Cutaneous Melanoma; Unresectable Lung Non-Small Cell Carcinoma; Unresectable Mucosal Melanoma	Fred Hutchinson Cancer Center	2022-06-09	PHASE1
NCT06756061	RECRUITING	GVHD - Graft-Versus-Host Disease; Neoplasms; Haematopoietic Stem Cell Transplantation	Byung-Sik Cho	2025-01-15	PHASE2
NCT02974647	RECRUITING	Lymphoma	Memorial Sloan Kettering Cancer Center	2016-11	PHASE2
NCT06909136	ACTIVE_NOT_RECRUITING	Intermediate- and High-risk Myelofibrosis (MF) Patients With Splenomegaly	Suzhou Junjing BioSciences Co., Ltd.	2025-07-28	PHASE1; PHASE2
NCT02955940	ACTIVE_NOT_RECRUITING	Pancreatic Cancer; Colorectal Cancer (CRC); Breast Cancer; Lung Cancer	Incyte Corporation	2016-11-30	PHASE2
NCT07796620	NOT_YET_RECRUITING	Acute Leukemia; Myelodysplastic Syndromes; Severe Aplastic Anemia (SAA)	Peking University People's Hospital	2026-10-01	PHASE1; PHASE2
NCT07184853	RECRUITING	Graft vs Host Disease	First Affiliated Hospital of Zhejiang University	2025-09-25
NCT06008808	RECRUITING	Graft Vs Host Disease; Graft-versus-host-disease; Graft Versus Host Disease	Washington University School of Medicine	2024-05-07	PHASE1
NCT05010005	RECRUITING	T-cell Lymphomas; NK-Cell Lymphomas; T-cell Prolymphocytic Leukemia; T-cell Large Granular Lymphocyte Leukemia	Memorial Sloan Kettering Cancer Center	2021-08-12	PHASE1
NCT07661979	NOT_YET_RECRUITING	Atopic Dermatitis	Wake Forest University Health Sciences	2026-12	PHASE4
NCT04061421	RECRUITING	MDS/MPN	Michael Savona	2021-11-24	PHASE1; PHASE2
NCT06079879	ACTIVE_NOT_RECRUITING	Essential Thrombocythemia	Merck Sharp & Dohme LLC	2023-12-31	PHASE3
NCT04644211	RECRUITING	Essential Thrombocythemia; Polycythemia Vera	Massachusetts General Hospital	2022-03-21	PHASE2
NCT07340723	RECRUITING	GVHD,Acute; Stem Cell Transplant Complications	Daihong Liu	2025-06-01	PHASE2
NCT07249346	RECRUITING	Leukemia; Myelodysplasia; Chronic Myelomonocytic Leukemia	Hannah Choe, MD	2026-01-14	PHASE2
NCT06388564	ACTIVE_NOT_RECRUITING	Chronic Graft-versus-host-disease	Incyte Corporation	2024-10-11	PHASE2
NCT06951971	NOT_YET_RECRUITING	Hemophagocytic Lymphohistiocytosis (HLH)	The First Affiliated Hospital of Soochow University	2025-06-01	PHASE2; PHASE3
NCT07366801	RECRUITING	Acute Myeloid Leukemia, Relapsed; Acute Lymphoblastic Leukemia, High Risk; Acute Myeloid Leukemia, High Risk; Acute Lymphoblastic Leukemia, Relapse	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	2025-09-03	PHASE2; PHASE3
NCT07032727	RECRUITING	Targeted Therapy; IDH1-Mutated Malignancies; Mutations	M.D. Anderson Cancer Center	2025-09-12	PHASE2
NCT06936566	RECRUITING	Acute Graft-versus-host Disease; Allogeneic Bone Marrow Transplantation; Adverse Effects	John Levine	2025-05-14	PHASE2
NCT05980806	RECRUITING	Myelofibrosis; Moderate Thrombocytopenia; Mild Thrombocytopenia	Karyopharm Therapeutics Inc	2024-04-22	PHASE2
NCT02494882	ACTIVE_NOT_RECRUITING	Acute Lymphoblastic Leukemia	Memorial Sloan Kettering Cancer Center	2015-06-29	PHASE1
NCT06120140	ACTIVE_NOT_RECRUITING	Carcinoma, Non-Small-Cell Lung	Janssen Research & Development, LLC	2024-02-16	PHASE2
NCT05762640	RECRUITING	Haemophagocytic Lymphohistiocytosis	Assistance Publique - Hôpitaux de Paris	2024-11-10	PHASE2
NCT04176198	RECRUITING	Myelofibrosis	Sumitomo Pharma America, Inc.	2019-12-16	PHASE1; PHASE2
NCT04279847	ACTIVE_NOT_RECRUITING	Myelofibrosis; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome; Myeloproliferative Neoplasm; Relapsed or Refractory Primary Myelofibrosis; Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis); ET (Essential Thrombocythemia)	Incyte Corporation	2021-02-23	PHASE1
NCT06804811	RECRUITING	NonSegmental Vitiligo	Incyte Corporation	2025-11-13	PHASE3
NCT06225310	RECRUITING	Multiple Myeloma in Relapse; Multiple Myeloma, Refractory	Oncotherapeutics	2024-08-06	PHASE1
NCT07278856	RECRUITING	Follicular Helper T-Cell Lymphoma; Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type; Follicular Helper T-Cell Lymphoma, Follicular-Type; Follicular Helper T-Cell Lymphoma, Not Otherwise Specified; Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Peripheral T-Cell Lymphoma, Not Otherwise Specified	City of Hope Medical Center	2025-12-16	PHASE1
NCT03954236	ACTIVE_NOT_RECRUITING	Non-sclerotic Cutaneous Chronic Graft-versus-host Disease	Memorial Sloan Kettering Cancer Center	2019-05-14	PHASE2
NCT07197112	NOT_YET_RECRUITING	Acute Graft Versus Host Disease Grade II-IV; Acute Graft vs Host Disease	Ruijin Hospital	2025-10-01	PHASE2
NCT03069326	ACTIVE_NOT_RECRUITING	Myelofibrosis	Memorial Sloan Kettering Cancer Center	2017-02-27	PHASE2
NCT05371964	ACTIVE_NOT_RECRUITING	Myelofibrosis	Geron Corporation	2022-05-04	PHASE1
NCT06345495	RECRUITING	Splenomegaly; Myelofibrosis	M.D. Anderson Cancer Center	2024-10-01	PHASE2
NCT04454658	ACTIVE_NOT_RECRUITING	Myelofibrosis (MF)	AbbVie	2020-11-11	PHASE1
NCT05714072	RECRUITING	Myelofibrosis Due to and Following Polycythemia Vera	Memorial Sloan Kettering Cancer Center	2023-01-25	PHASE1
NCT04041050	ACTIVE_NOT_RECRUITING	Myeloproliferative Neoplasm	AbbVie	2019-11-08	PHASE1
NCT06479135	RECRUITING	Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis; Primary Myelofibrosis; MF	Kartos Therapeutics, Inc.	2024-06-03	PHASE3
NCT07356245	RECRUITING	T-cell Lymphoma; Graft Versus Host Disease; Lymphoma, T-Cell; Peripheral T Cell Lymphoma; T-cell Prolymphocytic Leukemia; Cutaneous T Cell Lymphoma; Adult T-cell Leukemia/Lymphoma; Primary Cutaneous T-Cell Non-Hodgkin Lymphoma	Jonathan Brammer	2026-02-12	PHASE2
NCT07238712	RECRUITING	Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia; Myelodysplastic Syndromes (MDS); Myeloprolipherative Neoplsm; Atypical Chronic Myeloid Leukemia	St. Petersburg State Pavlov Medical University	2025-05-10	PHASE2
NCT07049575	RECRUITING	Hidradenitis Suppurativa	Incyte Corporation	2025-11-03	PHASE1
NCT06150157	RECRUITING	Neoplasms	Janssen Research & Development, LLC	2023-12-20	PHASE1
NCT06770842	RECRUITING	Primary Myelofibrosis (PMF); Post Polycythemia Myelofibrosis (PPV MF); Post Essential Thrombocythaemia Myelofibrosis (PET-MF)	The University of Hong Kong	2025-03-01	PHASE2
NCT06857240	RECRUITING	Dermatomyositis	The Cleveland Clinic	2025-06-01	PHASE2
NCT03286530	ACTIVE_NOT_RECRUITING	Acute Myeloid Leukemia; Acute Myeloid Leukemia in Remission; Allogeneic Stem Cell Transplantation	Massachusetts General Hospital	2017-11-03	PHASE2
NCT06199427	RECRUITING	Inborn Errors of Immunity	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	2023-11-21	PHASE2
NCT07340138	RECRUITING	Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis (Post-PV MF); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)	Novartis Pharmaceuticals	2026-04-15	PHASE1
NCT04282187	RECRUITING	Acute Myeloid Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Not Otherwise Specified; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis	University of Washington	2020-03-24	PHASE2
NCT04509700	ACTIVE_NOT_RECRUITING	B-Cell Malignancies	Incyte Corporation	2020-08-03	PHASE2
NCT06958211	ACTIVE_NOT_RECRUITING	Hidradenitis Suppurativa	Incyte Corporation	2025-06-12	PHASE3
NCT06959225	ACTIVE_NOT_RECRUITING	Hidradenitis Suppurativa	Incyte Corporation	2025-06-23	PHASE3
NCT03117751	ACTIVE_NOT_RECRUITING	Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma	St. Jude Children's Research Hospital	2017-03-29	PHASE2; PHASE3
NCT07802405	RECRUITING	MF With Splenomegaly	Henan Cancer Hospital	2023-11-21	PHASE1
NCT07588139	RECRUITING	Healthy Participants	Incyte Corporation	2026-05-18	PHASE1
NCT06462469	ACTIVE_NOT_RECRUITING	Steroid-refractory Acute Graft Versus Host Disease	Novartis Pharmaceuticals	2024-07-04	PHASE4
NCT03571321	RECRUITING	Acute Lymphoblastic Leukemia; ALL, Childhood; ALL	University of Chicago	2019-05-28	PHASE1
NCT03681561	RECRUITING	Hodgkin Lymphoma	Veronika Bachanova	2018-09-13	PHASE1; PHASE2
NCT06548360	RECRUITING	NonSegmental Vitiligo	Incyte Corporation	2025-01-24	PHASE3
NCT06832618	ACTIVE_NOT_RECRUITING	Atopic Dermatitis	Incyte Corporation	2025-06-17	PHASE3
NCT05592015	RECRUITING	T-Cell Large Granular Lymphocyte Leukemia	Jonathan Brammer	2023-05-03	PHASE2
NCT06756152	RECRUITING	Biphenotypic Acute Leukemia; Acute Lymphoblastic Leukemia; Myeloblastic Leukemia; Bilinear Leukemia; Malignant Lymphoma, Non-Hodgkin; Myelodysplastic Syndrome	Federal Research Institute of Pediatric Hematology, Oncology and Immunology	2024-07-10	PHASE2; PHASE3
NCT07725432	ACTIVE_NOT_RECRUITING	Immune-related Vitiligo-like-Depigmentation	University of Zurich	2024-07-25	PHASE2
NCT05622318	ACTIVE_NOT_RECRUITING	Graft-versus-host Disease	Medical College of Wisconsin	2023-08-29	PHASE2
NCT06008275	RECRUITING	Metastatic Triple-Negative Breast Carcinoma; Breast Cancer	Baylor Research Institute	2024-09-16	EARLY_PHASE1
NCT06397313	RECRUITING	Myelofibrosis	Ryvu Therapeutics SA	2024-09-19	PHASE2
NCT06209606	RECRUITING	Multiple Myeloma	Oncotherapeutics	2022-12-08	EARLY_PHASE1
NCT05423691	RECRUITING	Myelofibrosis	Cellenkos, Inc.	2022-12-27	PHASE1
NCT05132166	ACTIVE_NOT_RECRUITING	Graft Vs Host Disease	University Health Network, Toronto	2021-12-22	PHASE2
NCT06399029	ACTIVE_NOT_RECRUITING	Exanthema; Lichenoid Skin Rashes Under Anti-PD1 Tumor Therapy	University of Zurich	2024-10-10	PHASE2
NCT04384692	ACTIVE_NOT_RECRUITING	Primary Myelofibrosis; Secondary Myelofibrosis	Fred Hutchinson Cancer Center	2020-12-18	PHASE2
NCT02723994	COMPLETED	Leukemia	Incyte Corporation	2016-09-30	PHASE2
NCT05899725	COMPLETED	Severe Checkpoint Inhibitor Pneumonitis	Peking Union Medical College Hospital	2023-04-14
NCT06261021	RECRUITING	Discoid Lupus Erythematosus	Innovaderm Research Inc.	2024-04-19	PHASE2
NCT05123040	TERMINATED	Acute-graft-versus-host Disease	Masonic Cancer Center, University of Minnesota	2023-06-05	PHASE1; PHASE2
NCT04562389	ACTIVE_NOT_RECRUITING	Myelofibrosis	Karyopharm Therapeutics Inc	2021-03-11	PHASE3
NCT05909943	WITHDRAWN	Neuromyelitis Optica Spectrum Disorder Relapse	Tianjin Medical University General Hospital	2024-06-01	PHASE1; PHASE2
NCT06752694	ACTIVE_NOT_RECRUITING	Aplastic Anemia	Fred Hutchinson Cancer Center	2025-09-25	PHASE2
NCT01787487	COMPLETED	Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis	M.D. Anderson Cancer Center	2013-03-13	PHASE2
NCT07368673	COMPLETED	Vitiligo	Dow University of Health Sciences	2025-04-06	PHASE4
NCT06457425	ACTIVE_NOT_RECRUITING	MF,PMF,PPV-MF,PET-MF	Chengdu Zenitar Biomedical Technology Co., Ltd	2024-05-06	PHASE2
NCT04551131	ACTIVE_NOT_RECRUITING	Hemophagocytic Lymphohistiocytosis	St. Jude Children's Research Hospital	2021-07-13	PHASE1; PHASE2
NCT06607367	NOT_YET_RECRUITING	Poor Graft Function; Aplastic Anemia Idiopathic	Melbourne Health	2024-10-30	PHASE1; PHASE2
NCT05280509	RECRUITING	Myelofibrosis; Primary Myelofibrosis; Post-PV MF; Post-ET Myelofibrosis	Telios Pharma, Inc.	2022-06-09	PHASE1; PHASE2
NCT06664970	ENROLLING_BY_INVITATION	MDS	Peking Union Medical College Hospital	2024-11-06	PHASE2
NCT03610971	ACTIVE_NOT_RECRUITING	Chronic Phase Chronic Myeloid Leukemia; Chronic Myeloid Leukemia, Chronic Phase	H. Lee Moffitt Cancer Center and Research Institute	2019-11-19	PHASE2
NCT04908735	TERMINATED	Hematopoietic Stem Cell Transplant (HSCT); Bronchiolitis Obliterans (BO)	Children's Hospital Medical Center, Cincinnati	2021-11-12	PHASE2
NCT06695507	TERMINATED	Chronic Graft Versus Host Disease	Children's Hospital Medical Center, Cincinnati	2025-02-19	PHASE1
NCT05095649	UNKNOWN	Chronic Graft vs Host Disease	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	2022-03-24	PHASE2
NCT06388759	TERMINATED	Myelofibrosis	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2022-08-01	PHASE1
NCT06244862	UNKNOWN	Hemophagocytic Syndromes	Assistance Publique - Hôpitaux de Paris	2024-02-01	PHASE2
NCT06923228	COMPLETED	Atopic Dermatitis (AD)	CAGE Bio Inc.	2025-04-21	PHASE2
NCT05998408	ACTIVE_NOT_RECRUITING	Severe Aplastic Anemia; Single Lineage Cytopenias, T-LGL; Hypoplastic MDS	National Heart, Lung, and Blood Institute (NHLBI)	2024-02-20	PHASE1; PHASE2
NCT06213831	COMPLETED	Prurigo Nodularis	Incyte Corporation	2024-02-27	PHASE1
NCT06719024	RECRUITING	Vitiligo	Hospital Authority, Hong Kong	2024-11-29	PHASE2; PHASE3
NCT05440942	COMPLETED	Pancreatic Ductal Adenocarcinoma	Peter Hosein, MD	2023-01-19	PHASE1
NCT06238817	COMPLETED	Atopic Dermatitis	Incyte Corporation	2024-04-26	PHASE3
NCT06619522	WITHDRAWN	Myelofibrosis	M.D. Anderson Cancer Center	2024-09-11	PHASE2
NCT05914714	UNKNOWN	The Prophylactic Value of Ruxolitinib for aGVHD in HSCT Recipients of AA	Institute of Hematology & Blood Diseases Hospital, China	2023-07-01	PHASE2
NCT04455841	ACTIVE_NOT_RECRUITING	Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis	Incyte Corporation	2021-03-19	PHASE1; PHASE2
NCT05750823	COMPLETED	Nonsegmental Vitiligo With Genital Involvement	Incyte Corporation	2023-04-11	PHASE2
NCT05998395	COMPLETED	Kohlmeier Degos Disease With Neurologic Involvement; Kohlmeier-Degos Disease	National Heart, Lung, and Blood Institute (NHLBI)	2023-09-28	PHASE1; PHASE2
NCT03878199	TERMINATED	Essential Thrombocythemia; Myelofibrosis; Myeloproliferative Neoplasm; Polycythemia Vera; Secondary Acute Myeloid Leukemia	Ohio State University Comprehensive Cancer Center	2019-02-20	PHASE1; PHASE2
NCT04468984	ACTIVE_NOT_RECRUITING	Myelofibrosis (MF)	AbbVie	2020-08-31	PHASE3
NCT05696392	TERMINATED	Atopic Dermatitis	Incyte Corporation	2023-03-16	PHASE4
NCT02158858	COMPLETED	Myelofibrosis; Leukemia, Myelocytic, Acute; Myelodysplastic/Myeloproliferative Neoplasm; Myelodysplastic Syndrome (MDS); Preleukemia; Primary Myelofibrosis; Myeloproliferative Disorders; Bone Marrow Disease; Hematological Disease; Precancerous Conditions; Neoplasms; Leukemia; Neoplasms by Histologic Type; Essential Thrombocytosis	Constellation Pharmaceuticals	2014-07-16	PHASE1; PHASE2
NCT05817955	RECRUITING	MDS/MPN	The First Affiliated Hospital with Nanjing Medical University	2022-11-01	PHASE2
NCT05491304	UNKNOWN	Hemophagocytic Lymphohistiocytoses; Cytokine Storm	The Children's Hospital of Zhejiang University School of Medicine	2022-09-01	PHASE4
NCT05569538	UNKNOWN	Myelofibrosis	The University of Hong Kong	2022-12-01	PHASE2
NCT05764161	COMPLETED	Prurigo Nodularis	Incyte Corporation	2023-06-12	PHASE3
NCT04838704	COMPLETED	Graft Versus Host Disease	Zhejiang University	2021-04-01
NCT04269850	TERMINATED	Intestinal GVHD	St. Petersburg State Pavlov Medical University	2019-09-01	PHASE1; PHASE2
NCT04769895	ACTIVE_NOT_RECRUITING	Acute Graft Versus Host Disease in Intestine; Steroid Refractory GVHD	MaaT Pharma	2022-03-25	PHASE3
NCT06555081	COMPLETED	Healthy Participants	Incyte Corporation	2024-09-25	PHASE1
NCT05600855	COMPLETED	Transplant-Related Disorder	Institute of Hematology & Blood Diseases Hospital, China	2023-01-15	PHASE2
NCT03333187	ACTIVE_NOT_RECRUITING	Bone Marrow Fibrosis	Universitätsklinikum Hamburg-Eppendorf	2016-12-21	PHASE2
NCT05599256	UNKNOWN	Transplant-Related Disorder	Institute of Hematology & Blood Diseases Hospital, China	2023-02-09	PHASE2
NCT05755438	COMPLETED	Prurigo	Incyte Corporation	2023-03-10	PHASE3
NCT06075225	NOT_YET_RECRUITING	GVHD; Acute Stem Cell Transplant Complications	Sichuan University	2023-10-01	PHASE2
NCT04906746	ACTIVE_NOT_RECRUITING	Stage IV Non-small Cell Lung Cancer; Cachexia	Tu Dan	2022-02-23	EARLY_PHASE1
NCT06673654	COMPLETED	Atopic Dermatitis	Sun Pharmaceutical Industries, Inc.	2023-08-11	PHASE1
NCT03701698	TERMINATED	Acute GVHD	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	2018-11-01	PHASE2
NCT03110822	RECRUITING	Multiple Myeloma	Oncotherapeutics	2017-02-01	PHASE1
NCT06397313	Not yet recruiting	Myelofibrosis	Ryvu Therapeutics SA	2024-09	Phase 2
NCT02928978	COMPLETED	Ductal Carcinoma In Situ; Atypical Lobular Hyperplasia; Atypical Ductal Hyperplasia; Lobular Carcinoma In Situ	Julie Nangia	2018-05-13	PHASE2
NCT05906628	COMPLETED	Hand Eczema	Incyte Corporation	2023-07-31	PHASE2
NCT03654768	ACTIVE_NOT_RECRUITING	Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	SWOG Cancer Research Network	2018-10-24	PHASE2
NCT06388564	Not yet recruiting	Chronic Graft-versus-host-disease	Incyte Corporation	2024-07-08	Phase 2
NCT06251102	Not yet recruiting	Polycythemia Vera	Gruppo Italiano Malattie EMatologiche dell''Adulto	2024-07	--
NCT05413356	UNKNOWN	Bronchiolitis Obliterans Syndrome; Hematologic Malignancy	First Affiliated Hospital of Zhejiang University	2022-06-01	PHASE2
NCT05075681	UNKNOWN	Peripheral Blood Stem Cell Transplantation	Chinese PLA General Hospital	2021-11-01	PHASE1; PHASE2
NCT05456529	COMPLETED	Atopic Dermatitis (AD)	Incyte Corporation	2022-09-01	PHASE3
NCT05579769	TERMINATED	Hematologic Malignancy; Myeloid Malignancy	St. Jude Children's Research Hospital	2023-03-14	PHASE2
NCT03427866	COMPLETED	Myelofibrosis	Massachusetts General Hospital	2018-08-28	PHASE2
NCT06343792	Not yet recruiting	Steroid Refractory GVHD	ReAlta Life Sciences Inc.	2024-05	Phase 2
NCT05219864	WITHDRAWN	Hand Eczema	Incyte Corporation	2023-01-31	PHASE3
NCT05233410	WITHDRAWN	Chronic Hand Eczema (CHE)	Incyte Corporation	2023-01-31	PHASE3
NCT06310304	COMPLETED	Healthy Participants	Incyte Corporation	2024-03-26	PHASE1
NCT01644110	COMPLETED	Primary Myelofibrosis; Secondary Myelofibrosis; PMF; SMF; Post-PV MF; Post-ET MF	University of Ulm	2013-08	PHASE1; PHASE2
NCT04908280	COMPLETED	Discoid Lupus Erythematosus	University of Rochester	2022-05-04	PHASE2
NCT04414514	TERMINATED	Hidradenitis Suppurativa	Milton S. Hershey Medical Center	2022-10-13	PHASE2
NCT05872477	COMPLETED	Vitiligo	Centre Hospitalier Universitaire de Nice	2023-09-05	PHASE2
NCT05787860	COMPLETED	Seborrheic Dermatitis	Icahn School of Medicine at Mount Sinai	2022-11-15	PHASE2
NCT02784496	COMPLETED	Myelofibrosis	M.D. Anderson Cancer Center	2016-09-29	PHASE2
NCT04856137	NOT_YET_RECRUITING	Refractory Diffuse Large B-cell Lymphoma	National Health Research Institutes, Taiwan	2021-05-01	PHASE1; PHASE2
NCT05247489	COMPLETED	Vitiligo	Incyte Corporation	2022-05-05	PHASE2
NCT04328844	ACTIVE_NOT_RECRUITING	Solid Tumor, Adult; Non-Hodgkin Lymphoma, Adult; NSCLC; Myelofibrosis; Uveal Melanoma	iOnctura	2020-02-25	PHASE1
NCT00044304	ACTIVE_NOT_RECRUITING	Eosinophilic Myeloid Neoplasm; Hypereosinophilic Syndrome	National Institute of Allergy and Infectious Diseases (NIAID)	2002-09-26	PHASE2
NCT05635838	COMPLETED	Hidradenitis Suppurativa	Incyte Corporation	2022-12-07	PHASE2
NCT03153982	TERMINATED	Head and Neck Squamous Cell Carcinoma	University of California, San Francisco	2018-06-08	PHASE2
NCT05593432	COMPLETED	Cutaneous Lichen Planus	Incyte Corporation	2022-11-23	PHASE2
NCT04582604	UNKNOWN	Peripheral Blood Stem Cell Transplantation	Chinese PLA General Hospital	2020-09-01	PHASE1; PHASE2
NCT05593445	COMPLETED	Lichen Sclerosus	Incyte Corporation	2022-11-18	PHASE2
NCT03120624	ACTIVE_NOT_RECRUITING	Metastatic Endometrial Carcinoma; Recurrent Endometrial Adenocarcinoma; Recurrent Endometrial Carcinoma; Recurrent Endometrial Clear Cell Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Mixed Cell Adenocarcinoma; Recurrent Endometrial Serous Adenocarcinoma; Recurrent Endometrial Undifferentiated Carcinoma; Recurrent Uterine Corpus Carcinosarcoma; Stage IV Uterine Corpus Cancer AJCC v7	Mayo Clinic	2017-09-15	PHASE1
NCT04629508	COMPLETED	Myelofibrosis; Polycythemia Vera; Thrombocythemia	Incyte Corporation	2021-07-12	PHASE2
NCT04603495	ACTIVE_NOT_RECRUITING	Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis	Novartis Pharmaceuticals	2021-04-09	PHASE3
NCT04551053	TERMINATED	Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis	Incyte Corporation	2021-05-26	PHASE3
NCT05034822	COMPLETED	Atopic Dermatitis	Incyte Corporation	2021-12-16	PHASE1
NCT04551066	TERMINATED	Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis	Incyte Corporation	2021-05-24	PHASE3
NCT05127421	COMPLETED	Atopic Dermatitis	Incyte Corporation	2021-11-10	PHASE2
NCT04480086	TERMINATED	Myelofibrosis (MF)	AbbVie	2021-03-17	PHASE1
NCT04303403	UNKNOWN	Colorectal Cancer; Pancreatic Adenocarcinoma	National Cancer Centre, Singapore	2018-07-31	PHASE1
NCT04999878	UNKNOWN	Hemophagocytic Syndrome; T/NK-Cell Lymphoma	Zhengzhou University	2021-05-30	PHASE4
NCT05293717	COMPLETED	Chronic Hand Dermatitis	University of Rochester	2022-07-11	PHASE1; PHASE2
NCT05137496	UNKNOWN	Macrophage Activation Syndrome	Beijing Friendship Hospital	2022-06-01	PHASE3
NCT04281498	COMPLETED	Accelerated/Blast-phase Myeloproliferative Neoplasm; Chronic-phase Myelofibrosis; IDH2 Mutation	John Mascarenhas	2021-01-14	PHASE2
NCT05121142	COMPLETED	Acute-graft-versus-host Disease; Chronic Graft-versus-host-disease; Solid Organ Transplant	Children's Hospital Medical Center, Cincinnati	2021-10-27	PHASE1
NCT04921969	COMPLETED	Atopic Dermatitis	Incyte Corporation	2021-07-19	PHASE3
NCT04097821	TERMINATED	Myelofibrosis	Novartis Pharmaceuticals	2019-09-26	PHASE1; PHASE2
NCT04472598	COMPLETED	Myelofibrosis (MF)	AbbVie	2020-09-29	PHASE3
NCT04807777	TERMINATED	Advanced Cutaneous Squamous Cell Carcinoma	Columbia University	2022-04-07	PHASE2
NCT02493530	COMPLETED	Myelofibrosis; Polycythemia Vera	Vanderbilt-Ingram Cancer Center	2015-07	PHASE1
NCT04669210	COMPLETED	Graft-versus-host-disease; Stem Cell Transplant Complications; Acute Myeloid Leukemia; Acute Lymphoid Leukemia	St. Petersburg State Pavlov Medical University	2020-11-03	PHASE2
NCT03012230	COMPLETED	Metastatic Malignant Neoplasm in the Bone; Stage IV Breast Cancer AJCC v6 and v7; Triple-Negative Breast Carcinoma	Mayo Clinic	2017-12-06	PHASE1
NCT02876302	COMPLETED	Inflammatory Breast Cancer (IBC)	Dana-Farber Cancer Institute	2018-01-24	PHASE2
NCT02251821	COMPLETED	Primary Myelofibrosis; Secondary Myelofibrosis	Fred Hutchinson Cancer Center	2014-10-20	PHASE2
NCT04526223	UNKNOWN	Time of Hematopoietic Reconstruction	xuna	2017-04-20
NCT03952039	COMPLETED	Primary Myelofibrosis; Post-Polycythemia Vera; Myelofibrosis	Celgene	2019-09-09	PHASE3
NCT04354727	WITHDRAWN	Myelofibrosis	Ascentage Pharma Group Inc.	2020-12-15	PHASE1; PHASE2
NCT05447260	UNKNOWN	Myelofibrosis	Qilu Hospital of Shandong University	2022-06-10	PHASE4
NCT03674047	ACTIVE_NOT_RECRUITING	Other Cancer	Massachusetts General Hospital	2019-04-19	PHASE2
NCT04581954	COMPLETED	Coronavirus; Covid19; Pneumonia	Imperial College London	2020-10-02	PHASE1; PHASE2
NCT04839380	COMPLETED	Atopic Dermatitis	Incyte Corporation	2021-10-12	PHASE2
NCT04896385	COMPLETED	Vitiligo	Incyte Corporation	2021-06-23	PHASE2
NCT04530344	COMPLETED	Vitiligo	Incyte Corporation	2020-09-24	PHASE3
NCT04934670	TERMINATED	Steroid-Refractory Acute Graft Versus Host Disease	Xenikos	2022-06-16	PHASE3
NCT03773107	COMPLETED	Multiple Myeloma	Wake Forest University Health Sciences	2019-01-03	PHASE1; PHASE2
NCT04851535	COMPLETED	Myelofibrosis	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	2021-07-28	PHASE2
NCT03935555	TERMINATED	Primary Myelofibrosis (PMF); Post-Polycythemia Vera Myelofibrosis (Post-PV MF); Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)	Samus Therapeutics, Inc.	2019-08-12	PHASE1
NCT04218071	COMPLETED	Myelofibrosis	Actuate Therapeutics Inc.	2020-08-20	PHASE2
NCT04485260	UNKNOWN	Myelofibrosis	Kartos Therapeutics, Inc.	2021-01-28	PHASE1; PHASE2
NCT04424056	UNKNOWN	Covid19	Assistance Publique Hopitaux De Marseille	2020-09-01	PHASE3
NCT03722407	ACTIVE_NOT_RECRUITING	Chronic Myelomonocytic Leukemia; Leukemia	H. Lee Moffitt Cancer Center and Research Institute	2019-08-28	PHASE2
NCT04055844	COMPLETED	Acute Myeloid Leukemia; Myeloid and Monocytic Leukemia; Myelodysplastic Syndromes	Masonic Cancer Center, University of Minnesota	2020-02-17	PHASE2
NCT04217993	COMPLETED	Primary Myelofibrosis (PMF); Post-polycythemia Vera Myelofibrosis(Post-PV MF); Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	2020-01-07	PHASE2
NCT04061876	COMPLETED	aGVHD; Stem Cell Transplant Complications	Chinese PLA General Hospital	2019-08-25	PHASE2
NCT05021276	UNKNOWN	Safety and Efficacy	The First Affiliated Hospital of Soochow University	2020-12-15	PHASE4
NCT02152956	TERMINATED	AML	MacroGenics	2014-06-09	PHASE1; PHASE2
NCT04543279	TERMINATED	Myelofibrosis; Thrombocytopenia	Washington University School of Medicine	2021-05-03	PHASE2
NCT01712308	COMPLETED	Anemia; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis	M.D. Anderson Cancer Center	2013-02-21	PHASE2
NCT03558607	UNKNOWN	Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Disorder	Seoul National University Hospital	2018-05-17	PHASE1; PHASE2
NCT03669965	ACTIVE_NOT_RECRUITING	Polycythemia Vera	Kartos Therapeutics, Inc.	2019-01-15	PHASE2
NCT03222609	COMPLETED	Myelofibrosis (MF)	AbbVie	2017-10-31	PHASE2
NCT03683498	COMPLETED	Chronic Graft vs Host Disease	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	2018-09-25	PHASE1
NCT04492618	COMPLETED	Necrobiosis Lipoidica	Aaron R. Mangold	2020-09-29	PHASE2
NCT03774082	COMPLETED	Graft vs Host Disease	Novartis Pharmaceuticals	2020-05-20	PHASE2
NCT03616184	COMPLETED	Graft-versus-host-disease (GVHD)	University of Nebraska	2018-09-05	PHASE2
NCT02742324	COMPLETED	Myelofibrosis	French Innovative Leukemia Organisation	2016-03	PHASE1; PHASE2
NCT02638428	UNKNOWN	Relapsed Pediatric Solid Tumor; Refractory Pediatric Solid Tumor; Relapsed Pediatric AML; Refractory Pediatric AML	Samsung Medical Center	2015-12	PHASE2
NCT03755518	TERMINATED	Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis	Celgene	2019-03-27	PHASE3
NCT01712659	TERMINATED	T Cell Leukemia, Adult; Leukemia, Adult T-Cell; T Cell Leukemia, HTLV I Associated	National Cancer Institute (NCI)	2012-10-26	PHASE1; PHASE2
NCT02713386	COMPLETED	Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IIIA Ovarian Cancer 2014; FIGO Stage IIIA1 Ovarian Cancer; FIGO Stage IIIA2 Ovarian Cancer; FIGO Stage IIIB Ovarian Cancer 2014; FIGO Stage IIIC Ovarian Cancer 2014; FIGO Stage IVA Ovarian Cancer 2014; FIGO Stage IVB Ovarian Cancer 2014; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Stage III Fallopian Tube Cancer AJCC v7; Stage III Primary Peritoneal Cancer AJCC v7; Stage IIIA Fallopian Tube Cancer AJCC v7; Stage IIIA Primary Peritoneal Cancer AJCC v7; Stage IIIB Fallopian Tube Cancer AJCC v7; Stage IIIB Primary Peritoneal Cancer AJCC v7; Stage IIIC Fallopian Tube Cancer AJCC v7; Stage IIIC Primary Peritoneal Cancer AJCC v7; Stage IV Fallopian Tube Cancer AJCC v6 and v7; Stage IV Primary Peritoneal Cancer AJCC v7	NRG Oncology	2016-11-14	PHASE1; PHASE2
NCT03386214	TERMINATED	Myelofibroses	Washington University School of Medicine	2018-04-23	PHASE1
NCT03514069	COMPLETED	Glioma; Glioblastoma	Case Comprehensive Cancer Center	2018-06-05	PHASE1
NCT04348071	WITHDRAWN	COVID-19	University of Colorado, Denver	2021-07	PHASE2; PHASE3
NCT02973711	WITHDRAWN	Leukemia, Chronic Myeloid	University of Michigan Rogel Cancer Center	2018-01	PHASE1; PHASE2
NCT04354714	WITHDRAWN	COVID-19	Washington University School of Medicine	2020-06-30	PHASE2
NCT04338958	COMPLETED	Covid-19	University of Jena	2020-04-22	PHASE2
NCT02962388	TERMINATED	Essential Thrombocythemia	French Innovative Leukemia Organisation	2017-01-03	PHASE2; PHASE3
NCT02613598	COMPLETED	Hodgkin's Lymphoma; Lymphoma, Non-Hodgkin	University of Michigan Rogel Cancer Center	2016-05-12	PHASE1
NCT04334044	COMPLETED	COVID-19; Severe Acute Respiratory Syndrome Coronavirus 2	Grupo Cooperativo de Hemopatías Malignas	2020-09-01	PHASE1; PHASE2
NCT04477993	TERMINATED	Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV2	Vanderson Geraldo Rocha	2020-08-14	PHASE2; PHASE3
NCT02257138	COMPLETED	Blasts More Than 20 Percent of Bone Marrow Nucleated Cells; Blasts More Than 20 Percent of Peripheral Blood White Cells; Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia	M.D. Anderson Cancer Center	2015-02-12	PHASE1; PHASE2
NCT04052425	COMPLETED	Non-segmental Vitiligo	Incyte Corporation	2019-09-20	PHASE3
NCT04057573	COMPLETED	Non-segmental Vitiligo	Incyte Corporation	2019-10-03	PHASE3
NCT03491215	COMPLETED	Acute Graft Versus Host Disease	Novartis Pharmaceuticals	2019-02-21	PHASE1; PHASE2
NCT04377620	TERMINATED	COVID-19	Incyte Corporation	2020-05-24	PHASE3
NCT04348695	COMPLETED	Coronavirus Infection	Fundación de investigación HM	2020-04-12	PHASE2
NCT02718300	TERMINATED	MPN (Myeloproliferative Neoplasms)	Incyte Corporation	2017-02-08	PHASE2
NCT02420717	TERMINATED	Recurrent B Acute Lymphoblastic Leukemia; Recurrent Ph-Like Acute Lymphoblastic Leukemia; Refractory B Acute Lymphoblastic Leukemia; Refractory Ph-Like Acute Lymphoblastic Leukemia	M.D. Anderson Cancer Center	2015-07-15	PHASE2
NCT04331665	TERMINATED	COVID-19; Pneumonia	University Health Network, Toronto	2020-05-21
NCT04359290	COMPLETED	ARDS, Human; COVID	Philipps University Marburg	2020-07-01	PHASE2
NCT04446806	UNKNOWN	Safety and Efficacy	The First Affiliated Hospital of Soochow University	2019-06-01	PHASE4
NCT03613428	UNKNOWN	Acute T Cell Leukemia	Sichuan University	2018-12-01	PHASE1; PHASE2
NCT03878524	TERMINATED	Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Anatomic Stage IV Breast Cancer AJCC v8; Anemia; Ann Arbor Stage III Hodgkin Lymphoma; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Castration-Resistant Prostate Carcinoma; Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid System Neoplasm; Locally Advanced Pancreatic Adenocarcinoma; Metastatic Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Pancreatic Adenocarcinoma; Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Primary Myelofibrosis; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Hematologic Malignancy; Recurrent Hodgkin Lymphoma; Recurrent Myelodysplastic Syndrome; Recurrent Myelodysplastic/Myeloproliferative Neoplasm; Recurrent Myeloproliferative Neoplasm; Recurrent Non-Hodgkin Lymphoma; Recurrent Plasma Cell Myeloma; Recurrent Small Lymphocytic Lymphoma; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Chronic Myelomonocytic Leukemia; Refractory Hematologic Malignancy; Refractory Hodgkin Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Myelodysplastic Syndrome; Refractory Myelodysplastic/Myeloproliferative Neoplasm; Refractory Non-Hodgkin Lymphoma; Refractory Plasma Cell Myeloma; Refractory Primary Myelofibrosis; Refractory Small Lymphocytic Lymphoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Stage IV Prostate Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma	OHSU Knight Cancer Institute	2020-04-01	PHASE1
NCT04016116	WITHDRAWN	Cancer; Hematological Malignancy	NYU Langone Health	2019-12	PHASE2
NCT04456634	COMPLETED	Malaria	Medicines for Malaria Venture	2020-09-10	PHASE1
NCT02370706	COMPLETED	Myelofibrosis	Novartis Pharmaceuticals	2015-05-21	PHASE1
NCT01431209	COMPLETED	Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma	University of Nebraska	2011-08-12	PHASE2
NCT04362137	COMPLETED	Cytokine Storm (Covid-19)	Novartis Pharmaceuticals	2020-05-02	PHASE3
NCT02066532	COMPLETED	Metastatic Breast Cancer; Breast Carcinoma; HER-2 Positive Breast Cancer	Dawn L. Hershman	2014-06	PHASE1; PHASE2
NCT03257644	COMPLETED	Atopic Dermatitis	Incyte Corporation	2017-09-21	PHASE1
NCT04366232	TERMINATED	Covid-19	Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer	2020-08-19	PHASE2
NCT04374149	COMPLETED	Cytokine Release Syndrome; COVID19	Prisma Health-Upstate	2020-04-30	PHASE2
NCT04414098	UNKNOWN	COVID-19	Marcelo Iastrebner	2020-06-01	PHASE2
NCT02587598	TERMINATED	Solid Tumors	Incyte Corporation	2015-12-29	PHASE1; PHASE2
NCT03123588	TERMINATED	MPN (Myeloproliferative Neoplasms)	Incyte Corporation	2017-11-14	PHASE2
NCT03515200	TERMINATED	Acute Lymphoblastic Leukemia, in Relapse; Acute Lymphoblastic Leukemia With Failed Remission	St. Jude Children's Research Hospital	2018-04-20	PHASE1
NCT04403243	COMPLETED	COVID 19	Lomonosov Moscow State University Medical Research and Educational Center	2020-05-08	PHASE2
NCT01981850	COMPLETED	Primary Myelofibrosis; Polycythemia Vera; Post-Essential Thrombocythemia Myelofibrosis	Hoffmann-La Roche	2013-10-01	PHASE2
NCT04120090	UNKNOWN	Hemophagocytic Lymphohistiocytosis	Beijing Friendship Hospital	2019-07-01	PHASE3
NCT04397367	COMPLETED	aGVHD; Stem Cell Transplant Complications	Chinese PLA General Hospital	2019-01-01	PHASE1; PHASE2
NCT01433445	COMPLETED	Idiopathic Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia-Vera Myelofibrosis	Novartis Pharmaceuticals	2011-11-01	PHASE1
NCT03112603	COMPLETED	Graft-versus-host Disease (GVHD)	Incyte Corporation	2017-06-29	PHASE3
NCT03041636	COMPLETED	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Untreated Chronic Lymphocytic Leukemia	M.D. Anderson Cancer Center	2017-03-08	PHASE2
NCT02917096	COMPLETED	Primary Myelofibrosis; Secondary Myelofibrosis	City of Hope Medical Center	2016-11-13	PHASE1
NCT03274778	WITHDRAWN	Prostate Cancer	Oncology Institute of Southern Switzerland	2017-09-01
NCT03144687	COMPLETED	MPN (Myeloproliferative Neoplasms)	Incyte Corporation	2018-01-26	PHASE2
NCT03795909	UNKNOWN	Hemophagocytic Lymphohistiocytosis	Capital Research Institute of Pediatrics	2017-03-01	PHASE1; PHASE2
NCT05663827	COMPLETED	Steroid Refractory GVHD	Yi-Lun Wang	2019-01-01	PHASE3
NCT01317875	COMPLETED	Myelofibrosis	Incyte Corporation	2011-03-31	PHASE1
NCT03920852	COMPLETED	Atopic Dermatitis	Incyte Corporation	2019-05-30	PHASE1
NCT03745638	COMPLETED	Atopic Dermatitis	Incyte Corporation	2018-12-20	PHASE3
NCT02092324	COMPLETED	Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Chronic Neutrophilic Leukemia	OHSU Knight Cancer Institute	2014-07-08	PHASE2
NCT03745651	COMPLETED	Atopic Dermatitis	Incyte Corporation	2018-12-20	PHASE3
NCT02396628	TERMINATED	Graft vs Host Disease	Prof. Dr. Nikolas von Bubnoff	2017-06-29	PHASE2
NCT03373877	TERMINATED	Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis	Samus Therapeutics, Inc.	2018-05-24	PHASE1
NCT02400463	COMPLETED	Hemophagocytic Syndrome (HPS)	University of Michigan Rogel Cancer Center	2016-02-05	PHASE2
NCT01751425	TERMINATED	Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission; Minimal Residual Disease; Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia	M.D. Anderson Cancer Center	2013-07-24	PHASE1
NCT04884191	COMPLETED	Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post- Essential Thrombocythemia Myelofibrosis	CTI BioPharma	2017-07-31	PHASE2
NCT02913261	COMPLETED	Corticosteroid Refractory Acute Graft vs Host Disease	Novartis Pharmaceuticals	2017-03-10	PHASE3
NCT02164500	COMPLETED	Recurrent Classical Hodgkin Lymphoma	University of Cologne	2015-10	PHASE2
NCT01895842	COMPLETED	Leukemia	M.D. Anderson Cancer Center	2014-02	PHASE1
NCT02711137	TERMINATED	Solid Tumors	Incyte Corporation	2016-05-18	PHASE1; PHASE2
NCT03395340	TERMINATED	Graft Versus Host Disease; JNS Kinase; Topical Administration	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	2018-11-19	PHASE2
NCT01914484	COMPLETED	Chronic Phase Chronic Myeloid Leukemia; Accelerated Phase Chronic Myeloid Leukemia; Blastic Phase Chronic Myeloid Leukemia; Philadelphia Positive Acute Lymphoblastic Leukemia; Resistant to Tyrosine Kinase Inhibitor Therapy	University Health Network, Toronto	2013-08-01	PHASE1; PHASE2
NCT01348490	COMPLETED	MPN (Myeloproliferative Neoplasms)	Incyte Corporation	2011-06-15	PHASE2
NCT02806375	COMPLETED	Primary Myelofibrosis; Myeloproliferative Disorders	St. Petersburg State Pavlov Medical University	2016-01	PHASE1; PHASE2
NCT02997280	COMPLETED	Graft Vs Host Disease	St. Petersburg State Pavlov Medical University	2016-08	PHASE2
NCT02912754	UNKNOWN	Leukemia, Lymphocytic, Chronic, B-Cell	Sunnybrook Health Sciences Centre	2017-03	PHASE1; PHASE2
NCT02072057	TERMINATED	Cancer Cachexia	Kantonsspital Aarau	2014-04-20	PHASE2
NCT01776723	COMPLETED	Myelomonocytic Leukemia	H. Lee Moffitt Cancer Center and Research Institute	2013-02-20	PHASE1; PHASE2
NCT03099304	COMPLETED	Vitiligo	Incyte Corporation	2017-06-07	PHASE2
NCT01375140	COMPLETED	Myeloproliferative Diseases	M.D. Anderson Cancer Center	2011-09-22	PHASE2
NCT02966353	COMPLETED	Primary Myelofibrosis; Post-Polycythemia Vera-Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis	Novartis Pharmaceuticals	2017-03-31	PHASE2
NCT02076191	COMPLETED	Myeloproliferative Neoplasms	John Mascarenhas	2014-02	PHASE1; PHASE2
NCT02267278	COMPLETED	Myeloproliferative Diseases	M.D. Anderson Cancer Center	2015-01-12	PHASE2
NCT03533790	UNKNOWN	Hemophagocytic Lymphohistiocytosis	Beijing Friendship Hospital	2018-06	PHASE3
NCT01693601	COMPLETED	Myelofibrosis	John Mascarenhas	2013-01	PHASE1; PHASE2
NCT01795677	COMPLETED	Myelofibrosis	French Innovative Leukemia Organisation	2012-12	PHASE2
NCT02779283	COMPLETED	Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia	OHSU Knight Cancer Institute	2016-01-13	PHASE1
NCT01787552	COMPLETED	Primary Myelofibrosis; Thrombocytosis; Essential Thrombocythemia; Polycythemia Vera; Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Blood Coagulation Disorders; Blood Platelet Disorders; Hemorrhagic Disorders	Novartis Pharmaceuticals	2013-05-08	PHASE1; PHASE2
NCT02253277	COMPLETED	Chronic Myeloid Leukemia	Novartis Pharmaceuticals	2015-02-18	PHASE1
NCT02475655	COMPLETED	HIV Infections	National Institute of Allergy and Infectious Diseases (NIAID)	2016-05-16	PHASE2
NCT02953678	COMPLETED	Graft-versus-host Disease (GVHD)	Incyte Corporation	2016-12-30	PHASE2
NCT03011892	COMPLETED	Atopic Dermatitis	Incyte Corporation	2017-01-09	PHASE2
NCT02593929	WITHDRAWN	Head and Neck Squamous Cell Carcinoma	University of Pittsburgh	2017-01	EARLY_PHASE1
NCT02292446	COMPLETED	Polycythemia Vera	Novartis Pharmaceuticals	2014-11-21	PHASE3
NCT02436135	TERMINATED	Myelofibrosis	Gilead Sciences	2015-06-05	PHASE1
NCT02145637	COMPLETED	NSCLC	Yonsei University	2015-05-07	PHASE1
NCT01392443	COMPLETED	Primary Myelofibrosis (MF); Post-Polycythemia Vera (PV) MF; Post-Essential Thrombocythemia (ET) MF	Novartis Pharmaceuticals	2010-10-14	PHASE2
NCT01790295	TERMINATED	Primary Myelofibrosis; Post Polycythemia Vera Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis	John Mascarenhas	2013-11	PHASE2
NCT02598297	TERMINATED	Myelofibrosis With High Molecular Risk Mutations	Novartis Pharmaceuticals	2016-02-03	PHASE3
NCT02553330	TERMINATED	Alopecia Areata	Incyte Corporation	2015-11-18	PHASE2
NCT02155465	COMPLETED	Lung Cancer	Memorial Sloan Kettering Cancer Center	2014-06	PHASE1; PHASE2
NCT01965119	COMPLETED	Relapsed or Refractory Hodgkin Lymphoma; Primary Mediastinal Large B-cell Lymphoma	Samsung Medical Center	2013-11-15	PHASE2
NCT01620216	TERMINATED	Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Chronic Myelomonocytic Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia	OHSU Knight Cancer Institute	2012-05-11	PHASE2
NCT02593760	COMPLETED	Myelofibrosis	Hoffmann-La Roche	2016-01-25	PHASE1
NCT02809976	COMPLETED	Vitiligo	Tufts Medical Center	2016-01	PHASE2
NCT02226172	TERMINATED	Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis	Pfizer	2014-10-06	PHASE2
NCT01702064	COMPLETED	Chronic Phase Chronic Myeloid Leukemia	H. Lee Moffitt Cancer Center and Research Institute	2013-02-21	PHASE1
NCT01969838	COMPLETED	Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis	Sierra Oncology LLC - a GSK company	2013-12-06	PHASE3
NCT02528877	WITHDRAWN	Acute Myeloid Leukemia in Remission; Primary Myelofibrosis; Primary Myelofibrosis, Prefibrotic Stage; Secondary Acute Myeloid Leukemia; Secondary Myelofibrosis	City of Hope Medical Center	2015-11	PHASE1
NCT02469974	WITHDRAWN	Myelofibrosis; MF	Marina Kremyanskaya	2015-05
NCT02101268	COMPLETED	Primary Myelofibrosis (PMF); Post-polycythemia Vera (Post-PV); Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)	Sierra Oncology LLC - a GSK company	2014-06-19	PHASE3
NCT01732445	COMPLETED	Anemia; Primary Myelofibrosis; Secondary Myelofibrosis	Mayo Clinic	2013-04	PHASE2
NCT02041429	COMPLETED	Recurrent Breast Cancer; Metastatic Breast Cancer	Dana-Farber Cancer Institute	2014-02	PHASE1; PHASE2
NCT02049450	COMPLETED	Thalassemia Major	Novartis Pharmaceuticals	2014-05-28	PHASE2
NCT01950780	COMPLETED	Alopecia Areata	Columbia University	2013-08	PHASE2
NCT01594216	COMPLETED	Estrogen-receptor Positive Invasive Metastatic Breast Cancer	Abramson Cancer Center at Penn Medicine	2012-04	PHASE2
NCT02119650	TERMINATED	NSCLC (Non-small Cell Lung Carcinoma)	Incyte Corporation	2014-02-11	PHASE2
NCT02117479	TERMINATED	Pancreatic Cancer	Incyte Corporation	2014-03	PHASE3
NCT02119676	TERMINATED	CRC (Colorectal Cancer)	Incyte Corporation	2014-03	PHASE2
NCT02119663	TERMINATED	Pancreatic Cancer	Incyte Corporation	2014-06	PHASE3
NCT02120417	TERMINATED	Breast Cancer	Incyte Corporation	2014-05	PHASE2
NCT02038036	COMPLETED	Polycythemia Vera	Novartis Pharmaceuticals	2014-03-25	PHASE3
NCT01822756	TERMINATED	Solid Tumors; Pancreatic Cancer	Incyte Corporation	2013-04	PHASE1
NCT02015208	COMPLETED	Chronic Lymphocytic Leukemia	Sunnybrook Health Sciences Centre	2014-04	PHASE1; PHASE2
NCT01877005	COMPLETED	Hodgkin's Lymphoma	The Lymphoma Academic Research Organisation	2013-07-04	PHASE2
NCT01562873	TERMINATED	Breast Cancer	Dana-Farber Cancer Institute	2012-06	PHASE2
NCT00934544	COMPLETED	Myelofibrosis	Novartis Pharmaceuticals	2009-07-01	PHASE3
NCT02087059	COMPLETED	Primary Myelofibrosis (MF)	Novartis Pharmaceuticals	2014-04	PHASE3
NCT02091752	TERMINATED	Primary Myelofibrosis	Novartis Pharmaceuticals	2014-09	PHASE2
NCT01164163	COMPLETED	Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific	Children's Oncology Group	2010-09	PHASE1
NCT01369498	COMPLETED	Myelofibrosis	Gilead Sciences	2011-06-30	PHASE2
NCT01523171	TERMINATED	Hematopoietic Neoplasm	Bristol-Myers Squibb	2012-04-30	PHASE2
NCT01632904	COMPLETED	Polycythemia Vera	Incyte Corporation	2012-06	PHASE3
NCT01243944	COMPLETED	Polycythemia Vera	Incyte Corporation	2010-10-27	PHASE3
NCT01423604	COMPLETED	Pancreatic Cancer	Incyte Corporation	2011-07	PHASE2
NCT01445769	COMPLETED	Primary Myelofibrosis; Post-Polycythemia Vera Myelofibrosis; Post-Essential Thrombocythemia Myelofibrosis	Incyte Corporation	2011-09	PHASE2
NCT01340651	COMPLETED	Myelofibrosis	Incyte Corporation	2011-03	PHASE2
NCT01251965	TERMINATED	Leukemia	M.D. Anderson Cancer Center	2010-12	PHASE1; PHASE2
NCT00952289	COMPLETED	MPN (Myeloproliferative Neoplasms)	Incyte Corporation	2009-08	PHASE3
NCT00639002	COMPLETED	Multiple Myeloma	Incyte Corporation	2008-03	PHASE2
NCT00726232	TERMINATED	Myeloproliferative Neoplasm (MPN)	Incyte Corporation	2008-08-20	PHASE2
NCT00778700	COMPLETED	Psoriasis	Incyte Corporation	2008-10-28	PHASE2
NCT00617994	COMPLETED	Psoriasis	Incyte Corporation	2007-08-31	PHASE2
NCT00820950	COMPLETED	Psoriasis	Incyte Corporation	2007-05-31	PHASE2
NCT00638378	TERMINATED	Prostate Cancer	Incyte Corporation	2008-02	PHASE2
NCT00509899	COMPLETED	Myelofibrosis; Polycythemia Vera; Thrombocytosis	Incyte Corporation	2007-06	PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-01-16)

Check the Ruxolitinib (INCB18424) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ruxolitinib selectively binds to and inhibits Janus kinases 1 and 2 (JAK1/2), blocking downstream STAT protein phosphorylation and disrupting key cytokine signaling pathways involved in cell proliferation. This inhibition triggers toxic mitophagy, induces autophagy, and enhances cell apoptosis, which effectively suppresses abnormal hematopoietic proliferation and pathogenic immune responses in clinical conditions such as myelofibrosis, polycythemia vera, and graft-versus-host disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).